

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/38414

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12N 15/00, 15/63, 15/74; C07H 21/00, 21/04; C07K 16/00

US CL : 536/23.1, 23.53; 435/320.1, 325, 455; 530/387.1, 387.3

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.53; 435/320.1, 325, 455; 530/387.1, 387.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NoneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,132,722 A (SIEMERS et al. ) 17 October 2000 (17.10.00), see entire document.	1-13, 15, 16, 18, 30, 27, and 30
Y	KERR. D.E. et al. Development and activities of a new melphalan prodrug designed for tumor-selective activation. Bioconj. Chem. 1998, Vol. 9, pages 255-259, see entire document.	1-13, 15, 16, 18, 20, 27, and 30
Y	KERR. D.E. et al. Comparison of Recombinant and synthetically formed monoclonal antibody-b-lactamase conjugates for anticancer prodrug activation. Bioconj. Chem. 1999, Vol. 10, pages 1084-1089, see entire document.	1-13, 15, 16, 18, 20, 27, and 30
Y	WORN. A. et al. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 2001, Vol. 305, pages 989-1010, see entire document.	1-13, 15, 16, 18, 20, 27, and 30

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;"

document member of the same patent family

Date of the actual completion of the international search

30 June 2003 (30.06.2003)

Date of mailing of the international search report

28 JUL 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Anne Marie S. Weihe

Telephone No. 703-308-1235

Form PCT/ISA/210 (second sheet) (July 1998)

BEST AVAILABLE COPY

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/38414

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 14,17,19,21-26,28,29 and 31-33  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

PCT/US02/38814

**Continuation of B. FIELDS SEARCHED Item 3:**

DIALOG-Medline, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST:USPatfull, PGPubs, EPO, JPO, Derwent  
search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated, fusion, fused, chimeric, adept